08:00 , Jan 12, 2015 |  BioCentury  |  Emerging Company Profile

Neutralizing RNAi

The negatively charged phosphate backbone of RNA is critical for the oligonucleotide's biological activity but also prevents its uptake into cells and limits its circulating half-life. Solstice Biologics LLC's ribonucleic neutrals platform could enable efficient...
07:00 , Oct 7, 2013 |  BC Week In Review  |  Financial News

GenomeDx Biosciences completes venture financing

GenomeDx Biosciences Inc., Vancouver, B.C.   Business: Diagnostic   Date completed: 9/30/13   Type: Venture financing   Raised: Not disclosed   Investors: Merck Global Health Innovation Fund; Baird Venture Partners; Aeris Capital AG; CD Ventures   ...
08:00 , Jan 16, 2012 |  BC Week In Review  |  Company News

GenomeDx Biosciences board of directors update

GenomeDx Biosciences Inc., Vancouver, B.C.   Business: Diagnostic, Cancer   Appointed: Mike Liang, partner at Baird Venture Partners; and George Rehm, managing partner at Aeris Capital AG   ...
07:00 , Sep 12, 2011 |  BC Week In Review  |  Financial News

Crescendo Bioscience completes venture financing

Crescendo Bioscience Inc., South San Francisco, Calif.   Business: Diagnostic   Date completed: 9/8/11   Type: Venture financing   Raised: $31 million   Investors: Aeris Capital AG; Mohr Davidow Ventures; Kleiner Perkins Caufield & Byers; individual investors   ...
08:00 , Nov 16, 2009 |  BC Week In Review  |  Company News

Tethys Bioscience board of directors update

Tethys Bioscience Inc., Emeryville, Calif.   Business: Diagnostic, Endocrine   Appointed: George Rehm, managing partner at Aeris Capital AG   ...
07:00 , Aug 24, 2009 |  BC Week In Review  |  Company News

Adamas Pharmaceuticals board of directors update

Adamas Pharmaceuticals Inc., Emeryville, Calif.   Business: Neurology, Infectious   Appointed: David Mahoney, a private equity investor; and George Rehm, managing partner at Aeris Capital AG   ...
07:00 , Aug 24, 2009 |  BC Week In Review  |  Financial News

Adamas Pharmaceuticals completes venture financing

Adamas Pharmaceuticals Inc., Emeryville, Calif.   Business: Neurology, Infectious   Date completed: 8/18/09   Type: Venture financing   Raised: $40 million   Investors: Aeris Capital AG; DAG Ventures; Mohr Davidow Ventures; Northgate Capital   ...